ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0336

Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe

Laure Gossec1, Jessica Walsh2, Kaleb Michaud3, Elizabeth Holdsworth4, Steven Peterson5, Sophie Meakin4, Nicola Booth4, Soumya Chakravarty6, James Piercy4 and Alexis Ogdie7, 1Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, 2University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 3University of Nebraska Medical Center, Omaha, NE, 4Adelphi Real World, Bollington, United Kingdom, 5Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, 6Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, 7Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: Anxiety, depression, Psoriatic arthritis, quality of life

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I: Psoriatic Arthritis

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in a real-world clinical setting. The objective of this study was to describe the prevalence of anxiety and/or depression in PsA patients, assess concordance in reported anxiety and/or depression between patients and physicians, and compare clinical and patient reported outcomes (PROs) in patients who report anxiety and/or depression and those who do not.

Methods: A cross-sectional study among patients with PsA recruited by rheumatologists and dermatologists was conducted in France, Germany, Italy, Spain, UK and US.  Data were collected Jun-Aug 2018 via physician-completed patient record forms and patient self-completed forms. Physicians reported patient demographic, disease characteristics and diagnosed anxiety and/or depression. Patients reported experience of PsA-related anxiety and/or depression, quality of life [QoL] (EQ5D-5L), work productivity (WPAI), disability (HAQ-DI), and disease impact (PsAID12). Patients were compared according to patient reported anxiety and/or depression using parametric tests and non-parametric tests. Multivariate regressions explored impact of anxiety and/or depression on PROs. Models adjusted for age, gender, employment status, BMI, no. of joints affected, body surface area (BSA).

Results: Data were collected from 688 physician-patient pairs (524 EU; 164 US). Physicians reported anxiety and/or depression in 14.2% of patients (EU 13.3%; US 16.2%), while 36.6% (EU 36.3%; US 37.8%) of patients self-reported anxiety and/or depression. 71.4% of physician-patient pairs agreed on anxiety and/or depression presence or absence (Kappa = 0.31, fair agreement). Patients with anxiety and/or depression had worse QoL, higher work impairment, and greater disability (Table 2).

Conclusion: After adjusting for demographic and clinical factors, patients with anxiety and/or depression were found to have worse QoL, work productivity, and disability outcomes than those without. Differences between patient and physician reports of anxiety and/or depression suggest that physicians may not be aware of the extent to which PsA patients experience anxiety and/or depression.

Table 1: Demographic and clinical characteristics by patient-reported anxiety and/or depression

Table 2: Impact of anxiety or depression on PROs*


Disclosure: L. Gossec, Sandoz, 1, AbbVie, 5, 8, Amgen Inc., 5, 8, Biogen, 5, 8, Janssen, 5, 8, Celgene, 5, 8, Eli Lilly, 1, 5, 8, Novartis, 5, 8, Pfizer, 1, 5, 8, UCB Pharma, 5, 8, Sanofi, 5, 8; J. Walsh, Pfizer, 2, AbbVie, 2, 5, Eli Lilly, 5, UCB, 5, Janssen, 5, Novartis, 5, Amgen, 5; K. Michaud, Rheumatology Research Foundation, 2; E. Holdsworth, None; S. Peterson, Janssen Research & Development, LLC, 3; S. Meakin, None; N. Booth, None; S. Chakravarty, Janssen Scientific Affairs, LLC, 1, 3; J. Piercy, Adelphi Real World, 3; A. Ogdie, AbbVie, 5, Amgen, 2, 5, BMS, 1, Celgene, 1, Corrona, 1, Janssen, 1, Eli Lilly, 1, Novartis, 2, 5, Pfizer, 2, 5, National Institutes of Health/National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2, Rheumatology Research Foundation, 2, National Psoriasis Foundation, 2.

To cite this abstract in AMA style:

Gossec L, Walsh J, Michaud K, Holdsworth E, Peterson S, Meakin S, Booth N, Chakravarty S, Piercy J, Ogdie A. Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anxiety-and-depression-in-psoriatic-arthritis-psa-prevalence-and-impact-on-patient-reported-outcomes-real-world-survey-in-the-us-and-europe/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anxiety-and-depression-in-psoriatic-arthritis-psa-prevalence-and-impact-on-patient-reported-outcomes-real-world-survey-in-the-us-and-europe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences